BRPI0906519A2 - Compostos de 3h--[1,2,3]triazolo[4,5-d]pirimidina, seu uso como mtor cinase e inibidores de pi3 cinase, e sua síntese - Google Patents

Compostos de 3h--[1,2,3]triazolo[4,5-d]pirimidina, seu uso como mtor cinase e inibidores de pi3 cinase, e sua síntese

Info

Publication number
BRPI0906519A2
BRPI0906519A2 BRPI0906519-9A BRPI0906519A BRPI0906519A2 BR PI0906519 A2 BRPI0906519 A2 BR PI0906519A2 BR PI0906519 A BRPI0906519 A BR PI0906519A BR PI0906519 A2 BRPI0906519 A2 BR PI0906519A2
Authority
BR
Brazil
Prior art keywords
kinase
triazolo
synthesis
pyrimidine compounds
kinase inhibitors
Prior art date
Application number
BRPI0906519-9A
Other languages
English (en)
Inventor
Christoph Martin Dehnhardt
Aranapakam Mudumbai Venkatesan
Efren Guillermo Delos Santos
Zecheng Chen
Osvaldo Dos Santos
Natasja Brooijmans
Arie Zask
Jeroen Cunera Verheijen
Semiranis Ayral-Kaloustian
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of BRPI0906519A2 publication Critical patent/BRPI0906519A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0906519-9A 2008-01-15 2009-01-14 Compostos de 3h--[1,2,3]triazolo[4,5-d]pirimidina, seu uso como mtor cinase e inibidores de pi3 cinase, e sua síntese BRPI0906519A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2108408P 2008-01-15 2008-01-15
US3468008P 2008-03-07 2008-03-07
PCT/US2009/030939 WO2009091788A1 (en) 2008-01-15 2009-01-14 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses

Publications (1)

Publication Number Publication Date
BRPI0906519A2 true BRPI0906519A2 (pt) 2015-07-14

Family

ID=40377318

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906519-9A BRPI0906519A2 (pt) 2008-01-15 2009-01-14 Compostos de 3h--[1,2,3]triazolo[4,5-d]pirimidina, seu uso como mtor cinase e inibidores de pi3 cinase, e sua síntese

Country Status (21)

Country Link
US (1) US20090181963A1 (pt)
EP (1) EP2252296A1 (pt)
JP (1) JP2011510010A (pt)
KR (1) KR20100113567A (pt)
CN (1) CN102014914A (pt)
AP (1) AP2010005346A0 (pt)
AU (1) AU2009205501A1 (pt)
BR (1) BRPI0906519A2 (pt)
CA (1) CA2712267A1 (pt)
CO (1) CO6321259A2 (pt)
CR (1) CR11568A (pt)
DO (1) DOP2010000217A (pt)
EA (1) EA201001017A1 (pt)
EC (1) ECSP10010346A (pt)
IL (1) IL206820A0 (pt)
MA (1) MA32341B1 (pt)
MX (1) MX2010007746A (pt)
NI (1) NI201000119A (pt)
SV (1) SV2010003621A (pt)
WO (1) WO2009091788A1 (pt)
ZA (2) ZA201004603B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091268A1 (es) 2007-12-19 2009-09-19 Amgen Inc Derivados heterociclicos como inhibidores de pi3 quinasa
JP2011515462A (ja) * 2008-03-27 2011-05-19 アウククランド ウニセルビセス リミテッド 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
AU2010229468A1 (en) * 2009-03-27 2011-10-13 Vetdc, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US20100331305A1 (en) * 2009-06-24 2010-12-30 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
US8486939B2 (en) * 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
SG183155A1 (en) 2010-02-03 2012-09-27 Signal Pharm Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
ES2616238T3 (es) 2010-10-06 2017-06-12 Glaxosmithkline Llc, Corporation Service Company Derivados de bencimidazol como inhibidores de PI3 quinasa
EP2691384B1 (en) 2011-03-28 2016-10-26 MEI Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
PH12014500973A1 (en) * 2011-11-01 2014-06-16 Exelixis Inc Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies
WO2013152717A1 (zh) * 2012-04-10 2013-10-17 上海昀怡健康管理咨询有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
EP2852661A1 (en) 2012-05-23 2015-04-01 F. Hoffmann-La Roche AG Compositions and methods of obtaining and using endoderm and hepatocyte cells
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
AU2014254059B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for treating cancer
CA2908353C (en) 2013-04-17 2021-11-02 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2908957C (en) 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EA030726B1 (ru) 2013-04-17 2018-09-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ
HK1223286A1 (zh) 2013-05-29 2017-07-28 西格诺药品有限公司 7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法
JP6441910B2 (ja) * 2013-09-30 2018-12-19 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
CN106459048A (zh) 2014-05-14 2017-02-22 辉瑞公司 吡唑并吡啶类和吡唑并嘧啶类
WO2017087818A1 (en) * 2015-11-19 2017-05-26 The Regents Of The University Of Michigan Dual src/p38 kinase inhibitor compounds and their use as therapeutic agents
CA3063976A1 (en) 2017-05-23 2018-11-29 Mei Pharma, Inc. Combination therapy
ES2959860T3 (es) 2017-06-22 2024-02-28 Celgene Corp Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B
WO2020063636A1 (zh) * 2018-09-27 2020-04-02 苏州锐明新药研发有限公司 吡唑并嘧啶化合物及制备方法与制备抗癌症药物的应用
CN113549080B (zh) * 2021-08-27 2023-05-16 中国医学科学院放射医学研究所 一类1,2,3-三氮唑并嘧啶类化合物、其制备方法和用途
KR20240015978A (ko) 2022-07-28 2024-02-06 박수산 다층 수력 발전시스템
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives

Also Published As

Publication number Publication date
AU2009205501A1 (en) 2009-07-23
NI201000119A (es) 2011-05-04
ZA201004603B (en) 2011-03-30
CN102014914A (zh) 2011-04-13
SV2010003621A (es) 2011-07-05
EP2252296A1 (en) 2010-11-24
MA32341B1 (fr) 2011-06-01
CA2712267A1 (en) 2009-07-23
DOP2010000217A (es) 2010-07-31
EA201001017A1 (ru) 2011-02-28
WO2009091788A1 (en) 2009-07-23
ZA201005793B (en) 2011-04-28
AP2010005346A0 (en) 2010-08-31
JP2011510010A (ja) 2011-03-31
ECSP10010346A (es) 2010-08-31
KR20100113567A (ko) 2010-10-21
IL206820A0 (en) 2010-12-30
CR11568A (es) 2010-08-11
CO6321259A2 (es) 2011-09-20
MX2010007746A (es) 2010-08-18
US20090181963A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
ZA201005793B (en) 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds,their use as mtor kinase and pi3 kinase inhibitors,and their synthesis
CY2024030I1 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β
BRPI0817681A2 (pt) Compostos de tienopirimidina e pirazolopirimidina e seu uso como inibidores de mtor quinase e pi3 quinase
LTPA2020504I1 (lt) Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip Trk kinazės slopikliai
BRPI0813831A2 (pt) Compostos de heteroarila bicíclica e seu uso como inibidores de quinase
AU2008228964A8 (en) Pyrazolopyrimidine Analogs and their use as mTOR kinase and PI3 kinase inhibitors
PL2004654T3 (pl) Pochodne pirazolopirymidyny do stosowania jako antagonisty kinazy
BRPI0716749A2 (pt) Compostos pirido (2,3-d) pirimidinona e seu uso como inibidores pi3
DK2384326T3 (da) Pyrrolo[2,3-d]pyrimidinforbindelser
DK1973910T3 (da) Pyrrolo[3,2-c]pyridin-4-on-2-indolinon-proteinkinaseinhibitorer
DK2049500T3 (da) Cyclopenta [d]-pyrimidiner som AKT-proteinkinase-inhibitorer
BRPI0809998A2 (pt) Composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina cinase
BR112013017672A2 (pt) composto de imidazo[4,5-c]quinolin-2-ona e seu uso como inibidor duplo de quinase pi3/mtor
BRPI0919810A2 (pt) compostos heterocíclicos contendo nitrogênio, sua preparação e seu uso como medicamentos antibacterianos
NO20084526L (no) Tienpyrimidiner med MNKL/MNK2 inhiberende aktivitet for farmasøytiske sammensetninger
PT2217578E (pt) Compostos de [1,2,4]triazolo[1,5-a]piridina e [1,2,4]triazolo[1,5-c]pirimidina e a sua utilização
BRPI0908433A2 (pt) pirrolo[2,3-d]piridinas e empregos destas como inibidores tirosina cinase
BRPI0815043A2 (pt) mcp-1 mutantes antagonistas de glicosaminoglicanos e métodos para o seu uso
BRPI1008850A2 (pt) [1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase
BRPI0907931A2 (pt) Derivado de pirrolopirimidina como inibidor de pi3k e uso do mesmo
BRPI0919807A2 (pt) compostos nitrogenosos heterocíclicos , sua preparação e seu uso como medicamentos antibacterianos
SI2004654T1 (sl) Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
ES2439793T9 (es) Compuestos de pirimidina, su uso como inhibidores de la mTOR quinasa y de la PI3 quinasa, y su síntesis
BRPI0822239A2 (pt) Composto de pirazolo[1,5-a] pirimidina
EP2323663A4 (en) 4-amino-3- (imidazolyl) -PYRAZOLO- [3,4-D] pyrimidines

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.